Молодежный инновационный вестникМолодежный инновационный вестник2415-7805Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации6691UnclassifiedMODERN POSSIBILITIES OF PREVENTION OF CERVICAL CANCERBublikovaAnastasia<p>Student</p>nastyabublikova1907@mail.ruhttps://orcid.org/0000-0003-3886-5029KozarezovSvyatoslav<p>Student</p>sakozarezov@gmail.comhttps://orcid.org/0000-0001-7294-4973Voronezh State Medical University named after N.N. Burdenko1405202110S112161603202116032021Copyright © 2021, Молодежный инновационный вестник2021<p>Background:Cervical cancer remains one of the most common oncological diseases of the female reproductive system, with no downward trend. The increase in morbidity, the" rejuvenation " of the disease, and the persistence of high mortality determine the need to find new approaches to solving this problem. The leading role of the human papillomavirus in the pathogenesis of cervical cancer points to vaccination as a priority area for the prevention of sexually transmitted diseases.</p>
<p>The aim of the study: It is necessary to systematize current data on the vaccination of cases of cervical cancer associated with the human papillomavirus, to prove the effectiveness, to confirm the safety and to justify the need for immediate practical application of vaccination.</p>
<p>Materials and methods: Аnalysis of foreign and domestic publications (including those using databases) devoted to the vaccination of cervical cancer.</p>
<p>Results: Analysis of statistical data shows a decrease in the incidence of cervical cancer after the introduction of primary prevention against human papillomavirus in Europe, the United States and Australia.</p>
<p>Conclusion: the demonstration of the effectiveness of state programs for primary prevention of cervical cancer, the depressing forecast of experts regarding the increase in the incidence in our country in the coming years indicates the need for urgent implementation of the "ideal" national calendar of preventive vaccinations, including vaccination against the human papillomavirus.</p>
<p></p>Human papillomavirus, vaccination, vaccine, cervical cancer, prevention.Вирус папилломы человека, вакцинация, вакцина, рак шейки матки, профилактика.[Список литературы:][1. Pinidis P, Tsikouras P, Iatrakis G, Zervoudis S, Koukouli Z, Bothou A, et al. Human papilloma virus’ life cycle and carcinogenesis. Maedica (Buchar). 2016;11(1):48–54.][2. Tomar A, Kushwah A. Advances in human papilloma virus vaccines: a review. Int J Basic Clin Pharmacol. 2014;3(1):37–43.][3. Moscicki AB. HPV infections in adolescents. // Disease Markers. 2007. Vol. 73. P. 229–34.][4. Прилепская В.Н. Вакцинация против ВПЧ-ассоциированных заболеваний и рака шейки матки. // Медицинский совет. 2016. № 12. С. 120–5.][5. Castellsagué X, de Sanjosé S, Aguado T et al. HPV and cervical cancer in the world. // Vaccine. 2007. Vol. 25. Suppl. 3. P. 27–219][6. Arbyn M, Simoens C, Martin-Hirsch P. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. // Cochrane Database of Systematic Reviews. 2018. Issue 5. Art. №.CD009069.][7. Артымук Н. В., Марочко К. В. Эффективность выявления вируса папилломы человека при помощи устройства для самостоятельного забора вагинального отделяемого. Акушерство и гинекология. 2016; 3: 85–91. [Artymuk N. V., Marochko K. V.Effektivnost' vyyavleniya virusa papillomy cheloveka pri pomoshchi ustroistva dlya samostoyatel'nogo zabora vaginal'nogo otdelyae-mogo. Akusherstvo i ginekologiya. 2016; 3: 85–91. (in Russian)]][8. Garland SM. Kjaer SK, Muñoz N et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. // CID. 2016. Vol. 63. P. 519–27.][9. Paavonen J, Naud P, Salmerón J et al. HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. // Lancet. 2009. Vol. 374. P. 301–14.][10. Guo F, Cofie LE, Berenson AB. Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction. // Am J Prev Med. 2018. Vol. 55, N 2. P. 197–204]